AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

Baby boomers and users of weight loss drugs suffering from “facial sagging” are flocking to injectable aesthetic treatments ...

Evolus faces sector instability but shows strong growth potential. Learn why EOLS stock remains a “Buy” despite challenges, ...

The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox). AbbVie: Financial Performance Dissected Market Capitalization Analysis: With a profound ...

AbbVie ABBV underwent analysis by 17 analysts ... Allergan added several new products and drugs in aesthetics (including Botox). Market Capitalization Analysis: With a profound presence, the ...

Mint explains. In May 2024, the DoP received an anonymous complaint alleging AbbVie Healthcare India flew 30 doctors—experts in Botox and Juvederm—to Paris and Monaco. It said the firm treated ...

Other drugs in AbbVie's lineup, including Botox, migraine therapies Qulipta and Ubrelvy, cancer drug Venclexta, and antipsychotic medication Vrayalar, are also delivering strong sales growth.

Onabotulinumtoxin A is under clinical development by AbbVie and currently in Phase III for Unspecified Musculoskeletal Disorders.